Study guide
12.1 HDFN Pathophysiology
Scientist in Blood Banking, BB ASCP
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 Current Exam Facts 1.2 Eligibility Routes and Application 1.3 CMP, Credential Citation, and BB vs SBB
2 Donors and Collection
2.1 Donor Qualification 2.2 Collection Methods and Adverse Reactions 2.3 Special Donations
3 Processing, Storage, and Component QC
3.1 Processing: FDA/AABB Requirements, Testing, and Labeling 3.2 Anticoagulants, Additives, and Storage Temperatures 3.3 Transportation, Stored-Product Properties, and Expiration 3.4 Blood Component Quality Control
4 Blood Components
4.1 Red Blood Cells, Whole Blood, Washed, Frozen, and Rejuvenated 4.2 Platelets, Plasma, and Cryoprecipitated AHF 4.3 Granulocytes, Leukoreduced, and Irradiated Components 4.4 Apheresis Products, Fractionation, and Hematopoietic Progenitors
5 Blood Group Genetics and Transfusion Role
5.1 Basic and Molecular Genetics 5.2 Inheritance of Blood Groups 5.3 Immunogenicity and Antigen Prevalence
6 ABO and Lewis Systems
6.1 ABO Biochemistry and Antigens 6.2 ABO Antibodies, Discrepancies, and Subgroups 6.3 Lewis System
7 Rh System
7.1 Rh Genetics and Antigens 7.2 Weak D, Partial D, and Rh Antibodies 7.3 Rh Phenotyping and Clinical Significance
8 Kell, Duffy, Kidd, and MNS
8.1 Kell System 8.2 Duffy System 8.3 Kidd System 8.4 MNS System
9 Additional Systems and Antigens
9.1 P1PK, Globoside, and Ii Systems 9.2 Lutheran and Other Blood Group Systems 9.3 High- and Low-Prevalence Antigens 9.4 HLA, Platelet-Specific, and Granulocyte-Specific Antigens
10 Immunology Foundations
10.1 Immune Response, B and T Cells, Macrophages 10.2 Immunoglobulins: Classes, Structure, and Properties 10.3 Antigen-Antibody Interactions and Testing 10.4 Complement Pathways and Biologic Properties
11 Physiology, Hemostasis, Cytopenias, and Transplantation
11.1 Physiology of Blood 11.2 Hemostasis and Coagulation 11.3 Immune and Nonimmune Cytopenias 11.4 Solid Organ and HPC Transplantation
12 Hemolytic Disease of the Fetus and Newborn
12.1 HDFN Pathophysiology 12.2 HDFN Detection 12.3 HDFN Treatment and Prevention
13 Routine Serologic Testing
13.1 Blood Grouping Tests 13.2 Antibody Detection 13.3 Compatibility Testing and Crossmatch 13.4 Direct Antiglobulin Testing
14 Antibody Identification
14.1 Antibody Identification and Rule-Out 14.2 Clinical Significance, Dosage, and Multiple Antibodies 14.3 Panel Problem-Solving and Common Traps
15 Reagents and Special Techniques
15.1 Antiglobulin Sera, Grouping Sera, and Reagent Red Cells 15.2 Enzymes, Enhancement Media, and Lectins 15.3 Adsorption, Elution, Titration, and Cell Separations 15.4 Molecular, Solid-Phase, Column, ELISA, and Related Methods
16 Serologic QA and Special Reagents
16.1 Blood Sample Quality Assurance 16.2 Reagent and Procedure Quality Assurance 16.3 Thiol Reagents, Neutralization, Chloroquine, EGA, and Immunofluorescence
17 Indications and Component Therapy
17.1 Indications for Transfusion 17.2 Red Cell and Whole Blood Therapy 17.3 Platelet, Plasma, and Cryoprecipitate Therapy 17.4 Special Component Therapy
18 Adverse Effects of Transfusion
18.1 Immunologic Transfusion Reactions 18.2 Nonimmunologic Transfusion Reactions 18.3 Transfusion-Transmitted Diseases
19 Apheresis, Administration, and Patient Blood Management
19.1 Apheresis and Extracorporeal Circulation 19.2 Blood Administration 19.3 Patient Blood Management
20 Laboratory Operations
20.1 Quality Assessment and Troubleshooting 20.2 Quality Control, Proficiency Testing, and Regulation 20.3 Laboratory Safety 20.4 Laboratory Mathematics and Instrumentation
12.1 HDFN Pathophysiology
Key Takeaways Explain This Topic AI
HDFN is maternal IgG crossing the placenta via FcRn, coating antigen-positive fetal red cells, and triggering extravascular hemolysis in the spleen — IgM does not cause it.
Fetal disease is anemia that can progress to hydrops; after birth the placenta no longer clears bilirubin, so unconjugated hyperbilirubinemia can produce kernicterus.
ABO HDFN is usually a group O mother with an A or B infant, is often mild, can occur in a first pregnancy, and classically shows a weak or negative DAT plus spherocytes.
RhD HDFN is historically severe and almost always follows prior sensitization; the first antigen-positive pregnancy is usually spared unless the mother was already immunized by transfusion or an earlier pregnancy.
Anti-K suppresses fetal erythropoiesis on early progenitors, so titer and amniotic-fluid bilirubin underpredict anemia; also honor anti-c, anti-E, Duffy, Kidd, and anti-U.
Last updated: August 2026
12.1 HDFN Pathophysiology
Quick Answer: HDFN happens when maternal IgG crosses the placenta , coats antigen-positive fetal red cells , and triggers extravascular hemolysis . The fetus becomes anemic ; severe disease produces hydrops . After birth the placenta no longer clears bilirubin, so unconjugated hyperbilirubinemia can injure the brain ( kernicterus ). ABO HDFN is usually mild , can hit a first pregnancy (group O mother, A or B infant), and often shows a weak or negative DAT with spherocytes . RhD HDFN is the historical severe disease and almost always follows prior sensitization . Anti-K is different again: it suppresses fetal erythropoiesis , so titer underpredicts anemia.
The June 9, 2026 BB outline parks this entire disease at III.B.3 . Later sections in this chapter hand you the DAT, the eluate, Doppler, and the RhIG vial math. This section is the mechanism. If you cannot say why a first pregnancy is usually safe for anti-D but not for ABO, and why anti-K can wreck a fetus while the bilirubin looks modest, the detection and treatment items will not save you.
Only IgG crosses, and it has to find antigen
IgM does not cross the placenta. That single sentence is why naturally occurring anti-A and anti-B (mostly IgM) do not routinely destroy a group A fetus, and why a cold anti-M or anti-Le(a) is almost never an HDFN antibody. IgG is transported by the neonatal Fc receptor (FcRn) on syncytiotrophoblast. IgG1 and IgG3 cross most efficiently and are the subclasses that wreck red cells; IgG2 and IgG4 cross less well and fix complement poorly.
The antibody has to meet its antigen on the fetal red cell . Antigens that are poorly developed at birth (Lewis, I, Sd(a), Lutheran to a degree, and A and B themselves compared with adult cells) produce milder disease even when the mother has IgG. Antigens that are well developed early in fetal life (D, c, E, K, Fya, Jka, U) can produce serious disease. Kell is worse than its density on circulating cells suggests because it is already on early erythroid progenitors .
Once IgG is bound, fetal macrophages in the spleen (and to a lesser extent the liver) remove the coated cells. That is extravascular hemolysis . Intravascular lysis is not the usual HDFN picture. The fetus compensates by driving erythropoiesis : nucleated red cells spill into the circulation ( erythroblastosis fetalis ), the liver and spleen enlarge, and high-output cardiac failure plus hypoalbuminemia produce hydrops fetalis — ascites, pleural and pericardial effusions, skin edema, and a hydropic placenta. Untreated, the fetus dies.
After birth the problem becomes bilirubin
In utero the placenta clears unconjugated bilirubin into the mother. The anemic fetus is the emergency; jaundice is not. At delivery that clearance stops. The newborn liver has low UDP-glucuronyl transferase , so unconjugated bilirubin rises fast. Unconjugated bilirubin is lipid-soluble, crosses the blood–brain barrier, and stains basal ganglia and brainstem nuclei — kernicterus . Survivors can have athetoid cerebral palsy, hearing loss, and upward-gaze palsy.
So the disease has two clocks:
Fetal clock: anemia → hydrops → death.
Neonatal clock: hemolysis continues, bilirubin rises, brain is at risk.
That is why prenatal care chases MCA-PSV and hydrops , and why the newborn workup chases hemoglobin and bilirubin , not just a DAT strength. A 4+ DAT with a stable hematocrit and a modest bilirubin is not the same emergency as a weak DAT, a hemoglobin of 8 g/dL, and a climbing unconjugated bilirubin.
ABO HDFN: common, usually mild, first pregnancy allowed
ABO HDFN is almost always a group O mother with a group A or group B infant . Group O plasma contains anti-A,B with a real IgG fraction; group A and B mothers make far less IgG ABO antibody. The disease can appear in a first pregnancy because that IgG is naturally occurring — no prior transfusion or birth is required.
Why is it usually mild?
Fetal A and B antigens are not fully developed .
A and B substances in tissue and plasma adsorb a lot of the antibody before it reaches red cells.
The DAT is often weak or negative even when the infant is jaundiced. Do not use a negative DAT to rule out ABO HDFN in a group O mother with a jaundiced A or B neonate.
The smear classically shows spherocytes . Microspherocytes plus a group O mother is the ABO-HDFN postcard.
The dominant clinical problem is hyperbilirubinemia , not hydrops. Severe anemia and stillbirth from ABO HDFN are uncommon.
You do not titer anti-A,B for prenatal prediction. You do not give RhIG for ABO. You watch the newborn’s bilirubin and hemoglobin. Phototherapy is common; exchange is uncommon compared with historical anti-D disease.
RhD HDFN: historically severe, needs a first hit
Anti-D is an immune IgG . A D-neg woman does not have it until D+ red cells enter her circulation — a prior pregnancy , a miscarriage , or a transfusion of D+ red cells (or D+ platelets that carry residual red cells). The first antigen-positive pregnancy is usually spared because the sensitizing FMH is typically at delivery, and the primary immune response is slow and often IgM-first. The next D+ fetus meets IgG anti-D already in the mother. That is why RhIG exists , and why a history of unmatched transfusion can ruin a first pregnancy that would otherwise have been safe.
Once anti-D is present, disease can be severe. The DAT is strongly positive . Circulating cells hemolyze, nucleated red cells pour out, hydrops can appear in the second trimester, and untreated neonatal bilirubin can reach kernicterus. Before RhIG, anti-D was the leading cause of stillbirth from HDFN. It is still the antibody the exam uses as the prototype — just remember that anti-c and anti-K are the specificities that still produce a lot of real-world severe disease in countries that use RhIG well.
Anti-K and the other IgG villains
Anti-K does not play by the anti-D rulebook. Kell glycoprotein is expressed on early erythroid burst-forming and colony-forming units. Maternal anti-K can shut down fetal red-cell production . The fetus is anemic with inappropriately low reticulocytes and nucleated red cells . Amniotic-fluid bilirubin (the old Liley ΔOD450) underestimates the anemia because there is less circulating hemolysis. Titer correlates poorly with severity — a titer of 8 can hide a hydropic K+ fetus. Surveillance is MCA-PSV , and a K− father with reliable paternity lets you stand down.
Other IgG antibodies that cause HDFN and must be honored:
Anti-c — after anti-D, one of the most dangerous Rh antibodies; c is common, so most partners are c+.
Anti-E — can be mild or severe; often travels with anti-c.
Anti-Fya (and less often anti-Fyb) — IgG, clinically significant, enzyme-destroyed on the panel but fully able to cause HDFN.
Anti-Jka / anti-Jkb — can cause HDFN, usually less severe than anti-D or anti-K, but never call Kidd insignificant.
Anti-U, anti-s, anti-S — IgG MNS antibodies; anti-U is a high-prevalence problem in S−s−U− mothers of African ancestry and can be severe.
Anti-k, anti-Kpb, anti-Jsb, anti-PP1Pk — rare-donor, high-prevalence antibodies that can destroy a fetus.
Antibodies that essentially do not cause HDFN: Lewis (not on fetal red cells in meaningful amount), I (i is the cord antigen), P1 , most anti-M/N unless they are IgG and reactive at 37 °C, and HTLA antibodies. Do not titer anti-Le(a).
First pregnancy is not a magic shield
Write this on the inside of your skull:
Alloimmune RhD, c, E, K, Duffy, Kidd, U: first pregnancy is usually safe unless the woman was already immunized by transfusion , a prior unrecognized pregnancy , or another exposure to antigen-positive red cells. A “G1P0” stem that includes a trauma transfusion last year is not a first-hit case.
ABO: first pregnancy is fair game.
Once immunized, every subsequent antigen-positive fetus is at risk , and disease often worsens with later pregnancies.
Paternal zygosity decides the fetus. A D− woman with anti-D and an R2R2 (DcE/DcE) partner has a D+ fetus. A partner who is R1r is heterozygous; the fetus has a 50% chance of being D− and unaffected. That Punnett square is how you stop doing weekly Dopplers on a D− fetus. Chapter 5 already taught you to start HDFN squares with paternal zygosity , not with a guess from the mother’s type.
Comparison you must be able to recite
- Feature ABO HDFN RhD HDFN Kell HDFN
- Typical mother / infant O mother; A or B infant D-neg mother; D-pos infant K-neg mother; K-pos infant
First pregnancy Yes — IgG is naturally occurring Usually no — needs prior sensitization Usually no — needs prior sensitization
- DAT Weak or negative Strongly positive Positive; may be modest if few circulating cells
- Newborn smear Spherocytes Polychromasia, NRBCs, anemia Few retics/NRBCs for the degree of anemia
- Dominant problem Hyperbilirubinemia Anemia + hydrops , then bilirubin Marrow suppression and anemia
Titer Not used prenatally Useful until a critical titer , then Doppler Poorly predictive — do not wait on titer
- Surveillance Newborn Hb / bili MCA-PSV after critical titer MCA-PSV even at modest titer
- Prevention None RhIG Avoid K+ transfusions in girls and women of childbearing potential
- Exam traps
Calling ABO HDFN impossible in a first pregnancy. It is the one that likes first pregnancies.
Ruling out ABO HDFN because the DAT is negative. The DAT is allowed to be negative .
Treating anti-K like anti-D and waiting for a titer of 32 before you worry. Anti-K suppresses erythropoiesis ; Doppler early.
Promising a first D-neg pregnancy is safe when the stem includes a prior D+ transfusion .
Titration of anti-Le(a), anti-P1, or room-temperature anti-M as if they were anti-D.
Forgetting anti-c and anti-U as causes of severe non-D HDFN.